R&D Update

Creating a valuable and differentiated Exosome Delivery Platform

New Senior Appointment Strengthening Exosomes Expertise

11 January 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem cell and Exosome Technologies, announces that Dr Randolph Corteling will re-join ReNeuron on 3 March 2022, heading up the Research team as Vice President of Research and will report directly into the CEO.

Exosome platform update

Further collaborations underway to demonstrate the potential of ReNeuron’s proprietary exosome platform
Emerging data shows platform’s application to a range of novel therapeutics targeting the brain and other tissues

AGM Trading Update

10 September 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to provide a trading update ahead of today’s Annual General Meeting (“AGM”).